Market Overview

Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline

Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline

Radius Health Inc (NASDAQ: RDUS) has multiple catalysts that could drive near-term upside in the shares of the company, according to Morgan Stanley. 

Radius Health is an integrated biopharma company that specializes in therapies for osteoporosis, oncology and endocrine diseases.

The Analyst

Morgan Stanley analyst Matthew Harrison initiated coverage of the company with an Overweight rating and a $57 price target.

The Thesis

Radius is set to launch Tymlos, a bone builder for women with osteoporosis, Harrison said in a Monday note.

Despite Eli Lilly and Co (NYSE: LLY)'s presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, Harrison said Tymlos' pricing is 40 percent lower than Forteo's — and convenience could help it grab share.

"Key factors such as formulary wins with Express Scripts Holding Company (NASDAQ: ESRX) (9-12 percent of the market) and growing Medicare coverage (39 percent moving to 50-percent-plus in 2018) will accelerate the launch into 2H18," the analyst said.

Unlike the prevalent injectable therapies, the Radius patch could drive market growth, Harrison said. He estimates Radius could achieve 50 percent market share at peak, with $1 billion in peak sales in the late 2020s.

If the patch form of Tymlos succeeds, the analyst said the company can achieve $2 billion in peak sales, driving almost a four-fold potential return on Radius.

The consensus estimates for Radius have yet to account for the potential of elacestrant, a new agent for women who have not found success with prior breast cancer treatment, Harrison said. 

The Price Action

Radius Health shares are down over 10 percent over the past year. Shares were up 3.07 percent at the time of publication Monday at $39.93. 

Related Links:

Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer

What You Need to Know About Puma Biotech's 25% Slide

Latest Ratings for RDUS

Nov 2019Morgan StanleyMaintainsOverweight
Aug 2019CitigroupUpgradesNeutralBuy
May 2019CitiAssumesNeutral

View More Analyst Ratings for RDUS
View the Latest Analyst Ratings

Posted-In: breast cancerAnalyst Color Biotech Health Care Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (ESRX + LLY)

View Comments and Join the Discussion!

Latest Ratings

GRPNMorgan StanleyMaintains1.5
HMSYCantor FitzgeraldReiterates33.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at